Cargando…

Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis

AIM: Iridoid glycosides (IG) as the major active fraction of Syringa oblata Lindl. has a proven anti-inflammatory effect for ulcerative colitis (UC). However, its current commercial formulations are hampered by low bioavailability and unable to reach inflamed colon. To overcome the limitation, dual...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Chenzhe, Yu, Shen, Zhang, Xiaonan, Dang, Yanxin, Han, Dan-dan, Liu, Xin, Han, Janchun, Hui, Mizhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917316/
https://www.ncbi.nlm.nih.gov/pubmed/33658780
http://dx.doi.org/10.2147/IJN.S291090
_version_ 1783657673241133056
author Gao, Chenzhe
Yu, Shen
Zhang, Xiaonan
Dang, Yanxin
Han, Dan-dan
Liu, Xin
Han, Janchun
Hui, Mizhou
author_facet Gao, Chenzhe
Yu, Shen
Zhang, Xiaonan
Dang, Yanxin
Han, Dan-dan
Liu, Xin
Han, Janchun
Hui, Mizhou
author_sort Gao, Chenzhe
collection PubMed
description AIM: Iridoid glycosides (IG) as the major active fraction of Syringa oblata Lindl. has a proven anti-inflammatory effect for ulcerative colitis (UC). However, its current commercial formulations are hampered by low bioavailability and unable to reach inflamed colon. To overcome the limitation, dual functional IG-loaded nanoparticles (DFNPs) were prepared to increase the residence time of IG in colon. The protective mechanism of DFNPs on DSS-induced colonic injury was evaluated in rats. MATERIALS AND METHODS: We prepared DFNPs using the oil-in-water emulsion method. PLGA was selected as sustained-release polymer, and ES100 and EL30D-55 as pH-responsive polymers. The morphology and size distribution of NPs were measured by SEM and DLS technique. To evaluate colon targeting of DFNPs, DiR, was encapsulated as a fluorescent probe into NPs. Fluorescent distribution of NPs were investigated. The therapeutic potential and in vivo transportation of NPs in gastrointestinal tract were evaluated in a colitis model. RESULTS: SEM images and zeta data indicated the successful preparation of DFNPs. This formulation exhibited high loading capacity. Drug release results suggested DFNPs released less than 20% at the first 6 h in simulated gastric fluid (pH1.2) and simulated small intestine fluid (pH6.8). A high amount of 84.7% sustained release from NPs in simulated colonic fluid (pH7.4) was beyond 24 h. DiR-loaded NPs demonstrated a much higher colon accumulation, suggesting effective targeting due to functionalization with pH and time-dependent polymers. DFNPs could significantly ameliorate the colonic damage by reducing DAI, macroscopic score, histological damage and cell apoptosis. Our results also proved that the potent anti-inflammatory effect of DFNPs is contributed by decrease of NADPH, gene expression of COX-2 and MMP-9 and the production of TNF-α, IL-17, IL-23 and PGE2. CONCLUSION: We confirm that DFNPs exert protective effects through inhibiting the inflammatory response, which could be developed as a potential colon-targeted system.
format Online
Article
Text
id pubmed-7917316
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79173162021-03-02 Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis Gao, Chenzhe Yu, Shen Zhang, Xiaonan Dang, Yanxin Han, Dan-dan Liu, Xin Han, Janchun Hui, Mizhou Int J Nanomedicine Original Research AIM: Iridoid glycosides (IG) as the major active fraction of Syringa oblata Lindl. has a proven anti-inflammatory effect for ulcerative colitis (UC). However, its current commercial formulations are hampered by low bioavailability and unable to reach inflamed colon. To overcome the limitation, dual functional IG-loaded nanoparticles (DFNPs) were prepared to increase the residence time of IG in colon. The protective mechanism of DFNPs on DSS-induced colonic injury was evaluated in rats. MATERIALS AND METHODS: We prepared DFNPs using the oil-in-water emulsion method. PLGA was selected as sustained-release polymer, and ES100 and EL30D-55 as pH-responsive polymers. The morphology and size distribution of NPs were measured by SEM and DLS technique. To evaluate colon targeting of DFNPs, DiR, was encapsulated as a fluorescent probe into NPs. Fluorescent distribution of NPs were investigated. The therapeutic potential and in vivo transportation of NPs in gastrointestinal tract were evaluated in a colitis model. RESULTS: SEM images and zeta data indicated the successful preparation of DFNPs. This formulation exhibited high loading capacity. Drug release results suggested DFNPs released less than 20% at the first 6 h in simulated gastric fluid (pH1.2) and simulated small intestine fluid (pH6.8). A high amount of 84.7% sustained release from NPs in simulated colonic fluid (pH7.4) was beyond 24 h. DiR-loaded NPs demonstrated a much higher colon accumulation, suggesting effective targeting due to functionalization with pH and time-dependent polymers. DFNPs could significantly ameliorate the colonic damage by reducing DAI, macroscopic score, histological damage and cell apoptosis. Our results also proved that the potent anti-inflammatory effect of DFNPs is contributed by decrease of NADPH, gene expression of COX-2 and MMP-9 and the production of TNF-α, IL-17, IL-23 and PGE2. CONCLUSION: We confirm that DFNPs exert protective effects through inhibiting the inflammatory response, which could be developed as a potential colon-targeted system. Dove 2021-02-24 /pmc/articles/PMC7917316/ /pubmed/33658780 http://dx.doi.org/10.2147/IJN.S291090 Text en © 2021 Gao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gao, Chenzhe
Yu, Shen
Zhang, Xiaonan
Dang, Yanxin
Han, Dan-dan
Liu, Xin
Han, Janchun
Hui, Mizhou
Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis
title Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis
title_full Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis
title_fullStr Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis
title_full_unstemmed Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis
title_short Dual Functional Eudragit(®) S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis
title_sort dual functional eudragit(®) s100/l30d-55 and plga colon-targeted nanoparticles of iridoid glycoside for improved treatment of induced ulcerative colitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917316/
https://www.ncbi.nlm.nih.gov/pubmed/33658780
http://dx.doi.org/10.2147/IJN.S291090
work_keys_str_mv AT gaochenzhe dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT yushen dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT zhangxiaonan dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT dangyanxin dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT handandan dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT liuxin dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT hanjanchun dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis
AT huimizhou dualfunctionaleudragits100l30d55andplgacolontargetednanoparticlesofiridoidglycosideforimprovedtreatmentofinducedulcerativecolitis